Task 11/C25: Small Animal Models for Biodefense and Prion Disease

Southern Research Institute, Birmingham AL

Investigators

Abstract

The In Vitro and Animal Models for Emerging Diseases and Biodefense contract provides antimicrobial activity testing capabilities for Category A-C bacteria. Compounds demonstrating antimicrobial activity will receive further antimicrobial susceptibility testing against clinical panels of emerging and Category A-C bacterial pathogens. This contract also provides the development and standardization of small animal and non-human primate models, and may include efficacy testing of vaccines and/or therapeutics, including GLP studies to support product licensure. Vaccines and therapeutics which are efficacious in small animals may be further tested in non-human primate models.